B. Howell

Explorer Refining Liver Safety Risk Assessment

T. Parry, J. Iaci, A. Eisen, 2017 .

Systems pharmacology modeling of drug‐induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters

C. Battista, J. Woodhead, B. Howell, 2017, Clinical pharmacology and therapeutics.

Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials

S. Siler, T. Parry, B. Howell, 2017, Clinical pharmacology and therapeutics.

Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym®, a Mechanistic Model of Drug‐Induced Liver Injury

Y. Yang, D. Longo, B. Howell, 2016, CPT: pharmacometrics & systems pharmacology.

Intraluminal Carotid Artery Thrombus in COVID-19: Another Danger of Cytokine Storm?

B. Griffith, Suresh Patel, Mohammed F. Rehman, 2020, American Journal of Neuroradiology.

MITOsym®: A Mechanistic, Mathematical Model of Hepatocellular Respiration and Bioenergetics

P. Watkins, S. Siler, Y. Will, 2014, Pharmaceutical Research.